Immunohistochemical expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in invasive breast carcinoma

Bosnian Journal of Basic Medical Sciences

Volumn 9, Issue 2, 2009, Pages 125-130

  Kuskunovic, Suada ^a   Radovic, Svjetlana ^a   Doric, Mirsad ^a   Hukic, Ajna ^a   Babic, Mirsad ^a   Tomic, Ivana ^a   Selak, Ivan ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Breast carcinoma; Immunohistochemistry; Tissue inhibitor of metalloproteinase 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

ADULT; AGED; BREAST NEOPLASMS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67649399099     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2009.2831     Document Type: Article

References (12)

1. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2:161-174.
2. Johansson N., Ahonen M., Kähäri V.M. Matrix metalloproteinases in tumor invasion. Cell. Mol. Life Sci. 2000; 57:5-15.
3. Würtz S.O., Schrohl A.S., Sørensen N.M., et al. Tissue inhibitor of metalloproteinases-? in breast cancer. Endocr. Relat. Cancer 2005; 12:215-227.
4. Freije J., Balbin M., Pendas A.M., Sanchez L.M., Puente X.S., Lopez- Otin C. Matrix metalloproteinases and tumor progression. Adv. Exp. Med. Biol. 2005; 12:215-227.
5. McCarthy K., Maguire T., McGreal G., McDermott E., O'Higgins N., Duffy M.J. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer 1999; 84:44-48.
6. Nakopoulou L., Giannopoulou I., Stefanaki K., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 2002; 197:307-313.
7. Schrohl A.S., Christensen I.J., Pedersen A.N., et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinase-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell. Proteomics 2003; 2:164-172.
8. Sørensen I.V., Fenger C., Winther H., et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin fi xed paraffi n embedded tissue. J. Histochem. Cytochem. 2006; 54:1075-1086
9. Würtz S.O., Schrohl A.S., Mouridsen H., Brünner N. TIMP-1 as a tumor marker in breast cancer - An update. Acta Oncol. 2008; 47:580-590.
10. Nakopoulou L., Giannopoulou I., Lazaris A.Ch., et al. The favourable prognosic impact of tissue inhibitor of matrix metalloproteinase-1 protein overexpression in breast cancer cells. APMIS 2003:111:1027-1036.
11. Gonsalez L.O., Pidal I., Junquera S., et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear infl ammatory cells in breast cancer correlates with metastasisrelapse. Br. J. Cancer 2007; 97:957-963.
12. O-Charoenrat P., Rhys-Evans P.H., Eccles S.A. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2001; 127:813-820.